1. Scrip

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

Bristol Myers Squibb at ASH 2024 (Alaric DeArment/Scrip)

With the mega-blockbuster immunomodulatory drug (IMiD) class on its way to fully losing patent protection, Bristol Myers Squibb is banking on the cereblon E3 ligase modulatory drug (CELMoD) class to replace it, and the firm has been releasing early data on a pair of myeloma assets from the program nearing the market.

New York-based BMS presented Phase I/II data for the CELMoD candidate mezigdomide looking at ways of combining it with other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

More from Therapy Areas

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.